Severe lung injury induced by CD38 monoclonal antibody Daratumumab and bortezomib‐containing regimen in a patient with preexisting interstitial lung disease: a case report and literature review

This is the first case reporting Daratumumab and bortezomib-containing regimen-induced lung injury characterized by preexisting interstitial lung disease.